Literature DB >> 2422129

Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells.

M J Brunda, D Tarnowski, V Davatelis.   

Abstract

The ability of recombinant interferons (IFNs) to modulate recombinant interleukin-2 (rIL-2) augmentation of natural killer (NK)-cell activity and to modulate the generation of activated killer (AK) cells was examined. Incubation of murine spleen cells for 18 hr with either human rIL-2 or a human hybrid recombinant IFN alpha, rHuIFN-alpha A/D, which is active on murine cells, resulted in a dose-dependent increase in NK activity; however, recombinant murine IFN gamma, rMuIFN-gamma, had little activity. A more than additive augmentation of cytotoxicity was obtained when spleen cells were incubated with the combination of rIL-2 and rHuIFN-alpha A/D. Incubation of murine spleen cells with rIL-2 for 3 days resulted in a dose-dependent induction of AK cells which were cytotoxic to an NK-resistant tumor target cell. In contrast to the results observed on NK activity, incubation of spleen cells with rHuIFN-alpha A/D and rIL-2 inhibited AK-cell activity. Partially purified murine IFN-alpha had inhibitory activity comparable to that of rHuIFN-alpha A/D. The addition of rHuIFN-alpha A/D at the initiation of culture of spleen cells with rIL-2 (day 0) resulted in maximal inhibition of cytotoxicity; inhibition was reduced or absent if rHuIFN-alpha A/D was added on day 1 or 2 of culture. The proliferation of spleen cells incubated with rIL-2 was also inhibited by rHuIFN-alpha A/D. Addition of rMuIFN-gamma to spleen-cells and rIL-2 increased the cytolytic activity of AK cells and did not inhibit rIL-2-induced proliferation of spleen cells. Similar data were also obtained with human peripheral blood lymphocytes and recombinant cytokines. Incubation of human peripheral blood lymphocytes with rIL-2 and recombinant human IFN-alpha A (rHuIFN-alpha A) or recombinant human IFN-gamma (rHuIFN-gamma) resulted in a more than additive increase in NK activity. Human AK-cell cytotoxicity was inhibited by rHuIFN-alpha A but enhanced by rHuIFN-gamma. Thus recombinant IFNs have differential effects on rIL-2-induced cytotoxic cells, resulting in augmentation or inhibition of activity, which is dependent on both the type of IFN and the cytotoxic activity examined. These results may have important implications for the potential therapeutic use of combinations of these cytokines.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2422129     DOI: 10.1002/ijc.2910370522

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  Potentiated lymphokine-activated killer cell activity generated by low-dose interleukin-2 and mismatched double-stranded RNA.

Authors:  H R Hubbell; G D Gibson; R D Bigler
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.

Authors:  R K Puri; P Leland
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

3.  Interferon-gamma (IFN-gamma) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity--IFN-gamma-induced suppressive activity.

Authors:  M Toledano; C Mathiot; J Michon; G Andreu; D Lando; M Brandely; W H Fridman
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  In vitro enhancement of natural killer cell activity against herpesvirus-infected targets in patients with acute lymphocytic leukemia.

Authors:  J R McKolanis; A H Ragab; D S Schmid
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

5.  Effects of lipopolysaccharide on interleukin-2-induced cytotoxic activity of murine splenocyte cultures: role of prostaglandin E2 and interferons.

Authors:  D Vaillier; R Daculsi; N Gualde
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

6.  Determination of tumor necrosis factor alpha (TNF alpha) and interleukin 2 (IL 2) in women with idiopathic recurrent miscarriage.

Authors:  P Mallmann; R Mallmann; D Krebs
Journal:  Arch Gynecol Obstet       Date:  1991       Impact factor: 2.344

7.  Augmentation by transferrin of IL-2-inducible killer activity and perforin production of human CD8+ T cells.

Authors:  A Nakamura; S Sone; R Nabioullin; K Sugihara; M Munekata; Y Nishioka; A Nii; T Ogura
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

8.  Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2.

Authors:  S Morecki; S Revel-Vilk; C Nabet; M Pick; A Ackerstein; A Nagler; E Naparstek; M Ben Shahar; S Slavin
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  Combined effects of interferon alpha and interleukin 2 on the induction of a vascular leak syndrome in mice.

Authors:  R K Puri; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

10.  In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor models.

Authors:  A M Eggermont; P H Sugarbaker; R L Marquet; J Jeekel
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.